Pharmacological effects of meldonium: Biochemical mechanisms and biomarkers of cardiometabolic activity

Pharmacol Res. 2016 Nov;113(Pt B):771-780. doi: 10.1016/j.phrs.2016.01.019. Epub 2016 Feb 2.

Abstract

Meldonium (mildronate; 3-(2,2,2-trimethylhydrazinium)propionate; THP; MET-88) is a clinically used cardioprotective drug, which mechanism of action is based on the regulation of energy metabolism pathways through l-carnitine lowering effect. l-Carnitine biosynthesis enzyme γ-butyrobetaine hydroxylase and carnitine/organic cation transporter type 2 (OCTN2) are the main known drug targets of meldonium, and through inhibition of these activities meldonium induces adaptive changes in the cellular energy homeostasis. Since l-carnitine is involved in the metabolism of fatty acids, the decline in its levels stimulates glucose metabolism and decreases concentrations of l-carnitine related metabolites, such as long-chain acylcarnitines and trimethylamine-N-oxide. Here, we briefly reviewed the pharmacological effects and mechanisms of meldonium in treatment of heart failure, myocardial infarction, arrhythmia, atherosclerosis and diabetes.

Keywords: Cardioprotective; Long-chain acylcarnitines; Meldonium; Trimethylamine-N-oxide; l-Carnitine.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Biomarkers / metabolism*
  • Cardiotonic Agents / pharmacology
  • Cardiotonic Agents / therapeutic use
  • Cardiovascular Agents / pharmacology
  • Cardiovascular Agents / therapeutic use
  • Cardiovascular Diseases / drug therapy
  • Cardiovascular Diseases / metabolism
  • Humans
  • Methylhydrazines / pharmacology*
  • Methylhydrazines / therapeutic use*
  • Myocardium / metabolism*

Substances

  • Biomarkers
  • Cardiotonic Agents
  • Cardiovascular Agents
  • Methylhydrazines
  • 3-(2,2,2-trimethylhydrazine)propionate